Stock Events

CRISPR Therapeutics 

$63.56
1019
-$1.7-2.6% Friday 20:00

Statistics

Day High
65.39
Day Low
63.49
52W High
91.1
52W Low
37.55
Volume
1,078,430
Avg. Volume
1,238,769
Mkt Cap
5.4B
P/E Ratio
-23.45
Dividend Yield
-
Dividend
-

Earnings

8MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-2.36
-1.21
-0.05
1.1
Expected EPS
-1.42
Actual EPS
-1.43

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CRSP. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Editas Medicine
EDIT
Mkt Cap435.86M
Editas Medicine focuses on genome editing using CRISPR technology, directly competing in the gene editing space.
Intellia Therapeutics
NTLA
Mkt Cap2.19B
Intellia Therapeutics is a leading developer of CRISPR gene editing treatments, making it a direct competitor.
Beam Therapeutics
BEAM
Mkt Cap1.91B
Beam Therapeutics uses base editing, a form of gene editing that competes with CRISPR's approach to therapeutics.
Sangamo Therapeutics
SGMO
Mkt Cap119.17M
Sangamo Therapeutics specializes in genomic medicine, including gene editing and gene therapy, competing in the same therapeutic areas as CRISPR Therapeutics.
Bluebird bio
BLUE
Mkt Cap98.95M
bluebird bio focuses on gene therapy for genetic diseases and cancer, overlapping with CRISPR Therapeutics' target areas.
Alnylam Pharmaceuticals
ALNY
Mkt Cap19.33B
Alnylam Pharmaceuticals works on RNAi therapeutics, which, while a different technology, competes in the genetic disease treatment market.
Vertex Pharmaceuticals
VRTX
Mkt Cap124.05B
Vertex Pharmaceuticals collaborates with CRISPR Therapeutics on certain projects but also competes in developing other genetic therapies independently.
Biomarin Pharmaceutical
BMRN
Mkt Cap15.32B
BioMarin Pharmaceutical develops gene therapies for rare genetic disorders, competing for similar patient populations.
PTC Therapeutics
PTCT
Mkt Cap2.8B
PTC Therapeutics focuses on the discovery and commercialization of novel medicines, including treatments for genetic disorders, competing in the broader market for genetic therapies.
Regenxbio
RGNX
Mkt Cap693.52M
REGENXBIO is a biotechnology company specializing in the development of gene therapy products, competing in the gene therapy space with a focus on adeno-associated virus (AAV) vectors.

Analyst Ratings

78.36$Average Price Target
The highest estimate is $112.
From 13 ratings within the last 6 months. This is not an investment recommendation.
Buy
38%
Hold
54%
Sell
8%

About

Health Technology
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Show more...
CEO
Samarth Kulkarni
Employees
407
Country
CH
ISIN
CH0334081137
WKN
000A2AT0Z

Listings